Teva Pharm Adr (TEVA) Shareholder Accipiter Capital Management LLC Increased Holding

March 14, 2018 - By Peter Erickson

Gabe Hoffman increased its stake in Teva Pharm Adr (TEVA) by 198.89% based on its latest 2017Q3 regulatory filing with the SEC. Accipiter Capital Management Llc bought 402,040 shares as the company’s stock declined 15.11% while stock markets rallied. The hedge fund run by Gabe Hoffman held 604,185 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $10.63M, up from 202,145 at the end of the previous reported quarter. Accipiter Capital Management Llc who had been investing in Teva Pharm Adr for a number of months, seems to be bullish on the $18.88B market cap company. The stock decreased 3.91% or $0.755 during the last trading session, reaching $18.565. About 7.32M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since March 14, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: which released: “Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip” on January 18, 2018, also with their article: “Teva Pharmaceutical Industries Ltd ADR (TEVA) Names Kare Schultz As CEO” published on September 11, 2017, published: “Teva Needs More Than Job Cuts” on December 14, 2017. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: and their article: “Teva Pharmaceutical Industries Ltd (ADR) Stock Is About to Spike” published on February 12, 2018 as well as‘s news article titled: “Trade of the Day: Teva Pharmaceutical Industries Ltd (ADR) (TEVA)” with publication date: January 31, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 147 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Argus Research given on Tuesday, July 28. The firm earned “Overweight” rating on Tuesday, May 3 by Morgan Stanley. The stock has “Outperform” rating by Cowen & Co on Wednesday, April 5. The stock has “Outperform” rating by Wells Fargo on Friday, February 19. Maxim Group maintained the shares of TEVA in report on Thursday, July 13 with “Hold” rating. The firm has “Neutral” rating given on Friday, December 15 by Credit Suisse. The firm has “Buy” rating by Goldman Sachs given on Thursday, January 11. The company was maintained on Monday, July 27 by Standpoint Research. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Hold” rating given on Thursday, June 22 by Cantor Fitzgerald. As per Tuesday, September 12, the company rating was maintained by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: